Prevalence and diagnostic reclassification of sarcopenia in type 2 diabetes according to AWGS 2019 and AWGS 2025 criteria: a secondary cross-sectional analysis
Prävalenz und diagnostische Neuklassifikation von Sarkopenie bei Typ-2-Diabetes nach AWGS-2019- und AWGS-2025-Kriterien: sekundäre Querschnittsanalyse
BMC Endocrine Disorders · 13.08.2026 · 26 (1)
DOI: 10.1186/s12902-026-02428-2 ↗Auf einen Blick
Bei 250 Erwachsenen mit Typ-2-Diabetes war die Sarkopenieprävalenz nach AWGS 2025 höher als nach AWGS 2019. Die Übereinstimmung zwischen beiden Klassifikationen war mäßig.
Fragestellung
Unterscheidet sich die Sarkopenieprävalenz bei Typ-2-Diabetes zwischen den AWGS-2019- und AWGS-2025-Kriterien?
Methode
Sekundäre Analyse eines bestehenden Querschnittsdatensatzes von Februar bis November 2025; Erwachsene 40–90 Jahre mit Typ-2-Diabetes seit mindestens 1 Jahr; BIA, Handgriffkraft und körperliche Leistung nach Standardprotokollen.
Ergebnisse
Sarkopenie: 48,4 % (95 %-KI 42,2–54,6) nach AWGS 2025 vs. 23,2 % (95 %-KI 18,4–28,9) nach AWGS 2019; McNemar p < 0,001. Übereinstimmung 66,0 %, Cohen’s κ = 0,31; 74 Patienten (29,6 %) nur nach AWGS 2025.
Einschränkungen
Sekundäranalyse; weitere longitudinale Studien nötig, um die klinische Relevanz der Neuklassifikationen zu bestimmen.
Schlussfolgerung der Autor:innen
Die AWGS-2025-Kriterien klassifizierten deutlich mehr Patienten mit Typ-2-Diabetes als sarkopen. Die zusätzlich erfassten Teilnehmenden zeigten andere metabolische Merkmale, u. a. häufiger Insulinuse und höheres uACR.
Kernaussagen
- AWGS 2025 ergab eine höhere Sarkopenieprävalenz als AWGS 2019
- 66,0 % Übereinstimmung, Cohen’s κ = 0,31
- Zusätzlich erfasste Patienten hatten häufiger Insulinuse und höheres uACR
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Querschnittstudie in der Zeitschrift BMC Endocrine Disorders, online erschienen am 13.08.2026. Verfasst von Pitchaporn Phudphong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Dusit, Bangkok, …. Hauptthemen laut MEDLINE: Sarcopenia, Diabetes Mellitus, Type 2. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Sarcopenia is common in patients with type 2 diabetes mellitus (T2DM). In 2025, the Asian Working Group for Sarcopenia (AWGS) updated its diagnostic criteria by removing physical performance from the diagnostic algorithm and introducing BMI-adjusted appendicular skeletal muscle mass (ASM). These changes may influence sarcopenia detection in populations with altered body composition, including those with T2DM. This study compared sarcopenia prevalence and diagnostic transitions between AWGS 2019 and AWGS 2025 in patients with T2DM.
Methods
This study represents a secondary analysis of an existing cross-sectional dataset collected between February and November 2025. Participants were adults aged 40–90 years with T2DM treated for at least one year. Body composition was assessed using multi-frequency bioelectrical impedance analysis, and handgrip strength and physical performance were evaluated using standardized protocols. Sarcopenia was defined using the AWGS 2019 and 2025 criteria. Prevalence, clinical characteristics, and diagnostic transitions were compared.
Results
Among 250 participants (mean age 65.1 ± 8.5 years; mean BMI 27.9 ± 5.5 kg/m²), sarcopenia prevalence was substantially higher using the AWGS 2025 than the AWGS 2019 criteria (48.4%, 95% CI 42.2–54.6 vs. 23.2%, 95% CI 18.4–28.9; McNemar p < 0.001). Overall agreement between the two classifications was 66.0% (Cohen’s κ = 0.31). Increases were observed across most age groups. Patients classified as sarcopenic according to the AWGS 2025 criteria had higher BMI, consistent with the incorporation of BMI-adjusted ASM in the revised criteria, as well as more frequent insulin use and higher uACR. Diagnostic transitions showed that 74 patients (29.6%) met the AWGS 2025 criteria for sarcopenia but not the AWGS 2019 criteria.
Conclusions
The AWGS 2025 criteria classified substantially more patients with T2DM as having sarcopenia than the AWGS 2019 criteria. Participants additionally identified under the AWGS 2025 criteria exhibited distinct metabolic characteristics, including more frequent insulin use and elevated uACR. Further longitudinal studies are needed to determine the clinical relevance of these diagnostic reclassifications.
Trial registration
Not applicable. This study is a secondary analysis of previously collected cross-sectional data and does not involve any health care intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Dusit, Bangkok, 10300, Thailand.
- Department of Orthopedics Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. Adulkasem.n@gmail.com.
Zitieren
APA
Phudphong, P., Laoticharoen, K., & Adulkasem, N. (2026). Prevalence and diagnostic reclassification of sarcopenia in type 2 diabetes according to AWGS 2019 and AWGS 2025 criteria: a secondary cross-sectional analysis. BMC Endocrine Disorders, 26(1). https://doi.org/10.1186/s12902-026-02428-2
Vancouver
Phudphong P, Laoticharoen K, Adulkasem N. Prevalence and diagnostic reclassification of sarcopenia in type 2 diabetes according to AWGS 2019 and AWGS 2025 criteria: a secondary cross-sectional analysis. BMC Endocrine Disorders. 2026;26(1). doi:10.1186/s12902-026-02428-2
BibTeX
@article{Phudphong2026,
author = {Phudphong, Pitchaporn and Laoticharoen, Kwanchanok and Adulkasem, Nath},
title = {Prevalence and diagnostic reclassification of sarcopenia in type 2 diabetes according to AWGS 2019 and AWGS 2025 criteria: a secondary cross-sectional analysis},
journal = {BMC Endocrine Disorders},
year = {2026},
volume = {26},
number = {1},
doi = {10.1186/s12902-026-02428-2}
}
EUVIMED